Corvus Pharmaceuticals (CRVS) Current Deferred Revenue (2015 - 2018)

Corvus Pharmaceuticals' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $160000.0 for Q4 2018.

• In Q4 2018, Current Deferred Revenue fell 60.98% year-over-year to $160000.0; the TTM figure through Dec 2018 stood at $160000.0 (down 60.98% YoY), while the FY2018 annual figure was $160000.0, down 60.98% from the prior year.
• Current Deferred Revenue was $160000.0 for Q4 2018 at Corvus Pharmaceuticals, down from $435000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $435000.0 in Q3 2018 to a low of $160000.0 in Q4 2018.
• Historically, Current Deferred Revenue has averaged $350000.0 across 4 years, with a median of $386000.0 in 2017.
• The sharpest annual moves came in 2016 and 2018: Current Deferred Revenue jumped 69.51% in 2016, then sank 60.98% in 2018.
• A 4-year view of Current Deferred Revenue shows it stood at $223000.0 in 2015, then surged by 69.51% to $378000.0 in 2016, then advanced by 8.47% to $410000.0 in 2017, then tumbled by 60.98% to $160000.0 in 2018.
• The last three Current Deferred Revenue figures came in at $160000.0 (Q4 2018), $435000.0 (Q3 2018), and $427000.0 (Q2 2018), per Business Quant data.